BOLD-100

规格	价格	库存	数量
1mg	¥855.00	现货	1
5mg	¥1,710.00	现货	1
10mg	¥2,565.00	现货	1
10mM (in 1mL DMSO)	¥1,889.00	现货	1

产品描述 Description

BOLD-100 is a ruthenium-based anticancer agent^[1]. BOLD-100 has high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin, and is activated in the reducing tumor environment^[2]. BOLD-100 can disrupt endoplasmic reticulum (ER) homeostasis and induce ER stress and unfolded protein response (UPR^)[3].

In vitro, BOLD-100 (100μM) treatment of MCF7(2) cells for 72h significantly reduced S phase cells, increased G2/M phase cells, significantly reduced cell cycle proteins (such as RAD51, PCNA, ATM), and induced an increase in intracellular reactive oxygen species (ROS)^[4]. BOLD-100 (100μM) treatment of HCT116 cells for 24h enhanced the phosphorylation of eIF2A serine 51 in cells, but reduced the expression of the basal ER chaperone GRP78^[5]. BOLD-100 (0-200μM) has a significant inhibitory effect on malignant cell lines from various sources, such as liver cancer, melanoma, lung cancer and colon cancer, when treated for 72h, with an IC₅₀ value of 45-200μM^[6].

In vivo, BOLD-100 (30mg/kg) was treated by intravenous injection for 2 weeks in mice with Hep3B cell xenografts, which significantly inhibited the growth of transplanted tumors in mice, improved the survival rate of mice, and increased the number of apoptotic cells in tumor tissues. It has a synergistic therapeutic effect with sorafenib^[6]. BOLD-100 (50mg/kg) was treated by intravenous injection for 3 weeks in mice with VACO432 cell xenografts, but the inhibitory effect on tumor growth was not obvious. Combined treatment with AZD6738 can lead to a slowdown in tumor growth, but the tolerance is poor and the mice lose weight^[7].

References:
[1] Swaminathan S, Haribabu J, Karvembu R. From Concept to Cure: The Road Ahead for Ruthenium‐Based Anticancer Drugs[J]. ChemMedChem, 2024, 19(23): e202400435.
[2] Happl B, Brandt M, Balber T, et al. Synthesis and Preclinical Evaluation of Radiolabeled [103Ru] BOLD-100[J]. Pharmaceutics, 2023, 15(11): 2626.
[3] Ranzato E, Bonsignore G, Martinotti S. ER stress response and induction of apoptosis in malignant pleural mesothelioma: The Achilles heel targeted by the anticancer ruthenium drug BOLD-100[J]. Cancers, 2022, 14(17): 4126.
[4] Bakewell S, Conde I, Fallah Y, et al. Inhibition of DNA repair pathways and induction of ROS are potential mechanisms of action of the small molecule inhibitor BOLD-100 in breast cancer[J]. Cancers, 2020, 12(9): 2647.
[5] Baier D, Schoenhacker-Alte B, Rusz M, et al. The anticancer ruthenium compound BOLD-100 targets glycolysis and generates a metabolic vulnerability towards glucose deprivation[J]. Pharmaceutics, 2022, 14(2): 238.
[6] Heffeter P, Atil B, Kryeziu K, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo[J]. European Journal of Cancer, 2013, 49(15): 3366-3375.
[7] Griffin D, Carson R, Moss D, et al. Ruthenium Drug BOLD-100 Regulates BRAF MT Colorectal Cancer Cell Apoptosis through AhR/ROS/ATR Signaling Axis Modulation[J]. Molecular Cancer Research, 2024, 22(12): 1088-1101.

BOLD-100是一种基于钌元素的抗癌剂^[¹^]。BOLD-100具有高肿瘤靶向潜力，与血清蛋白如白蛋白和转铁蛋白强烈结合，并在还原性肿瘤环境中活化^[²^]。BOLD-100能够破坏内质网（ER）稳态并诱导ER应激和未折叠蛋白反应（UPR）^[³^]。

在体外，BOLD-100（100μM）处理MCF7(2)细胞72h，显著减少了S期细胞，增加了G2/M期细胞，显著减少了细胞周期蛋白（如RAD51、PCNA、ATM），诱导了细胞内活性氧（ROS）增加^[⁴^]。BOLD-100（100μM）处理HCT116细胞24h，增强了细胞中eIF2A丝氨酸51的磷酸化，但降低了基础ER伴侣GRP78的表达^[⁵^]。BOLD-100 (0-200μM) 处理肝癌、黑色素瘤、肺癌和结肠癌等多种来源的恶性细胞系72h，均有显著抑制作用，IC₅₀值为45-200μM^[⁶^]。

在体内，BOLD-100（30mg/kg）通过静脉注射治疗Hep3B细胞异种移植小鼠2周，显著抑制了小鼠体内移植瘤的生长，提高了小鼠存活率，增加了肿瘤组织中凋亡细胞数量，与索拉非尼（Sorafenib）具有协同治疗效果^[⁶^]。BOLD-100（50mg/kg）通过静脉注射治疗VACO432细胞异种移植小鼠3周，抑制肿瘤生长效果不明显，与AZD6738联合治疗能够导致肿瘤生长减缓，但耐受性较差，小鼠体重下降^[⁷^]。

实验参考方法 Experimental Reference Method

Cell experiment [1]:
Cell lines	MCF7(2) cells (MCF7(2) is a MCF7 derivative cell line that shows increased sensitivity to estrogen)
Preparation Method	Cells were grown at 70% confluence on 100mm in complete growth medium for 24h. The following day, cells were treated with vehicle or 100μM BOLD-100 for an additional 72h. Cells were then fixed in ethanol, and analyzed by the Flow Cytometry. Each experiment was repeated at least three times.
Reaction Conditions	100μM; 72h
Applications	Treatment of MCF7(2) cells with BOLD-100 significantly reduced the S phase and increased the G2/M phase compared with cells treated with the vehicle.
Animal experiment [2]:
Animal models	Balb/c SCID mice
Preparation Method	Hep3B xenografts were grown in Balb/c SCID mice and treated with BOLD-100 (30mg/kg; i.v.; once a week) and/or Sorafenib (25mg/kg; orally; five days a week) for 2 weeks when tumor nodules reached an average size of 25mm³. Tumour size was assessed by caliper measurement.
Dosage form	30mg/kg; once a week for 2 weeks; i.v.
Applications	Withregardto the anticancer activity, BOLD-100 as well as Sorafenib monotreatment induced a distinct delay in tumour growth.
References: [1]Bakewell S, Conde I, Fallah Y, et al. Inhibition of DNA repair pathways and induction of ROS are potential mechanisms of action of the small molecule inhibitor BOLD-100 in breast cancer[J]. Cancers, 2020, 12(9): 2647. [2]Heffeter P, Atil B, Kryeziu K, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo[J]. European Journal of Cancer, 2013, 49(15): 3366-3375.

产品文档 Product Documents

Purity:>98%

COA SDS Data Sheet

化学性质Chemical Properties

CAS 号

783324-98-1

同义词

NKP-1339 free base; IT-139 free base; KP-1339 free base

分子式

C14H12Cl4N4Ru

分子量

479.15 g/mol

保存条件

Store at -20°C

General tips

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。

Shipping Condition

评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

质量 (Mass)

体积 (Volume)

浓度 (Concentration)

分子量 (MW)

g/mol